Tagged with MSD,

Europe Speaking at the 2020 European Cancer Forum in Brussels, MSD’s Deepak Khanna outlines the progress that the company is making at the forefront of oncological innovation, the importance of multi-stakeholder collaboration, and the potential impact of a Europe-wide cancer plan.   As health stakeholders, we need to work across the…

Puerto Rico Merck (MSD outside of the USA) is celebrating its 70-year anniversary in Puerto Rico this year. Executive Managing Director Wendy Perry highlights the company’s extensive footprint on the island which includes commercial, manufacturing and clinical research operations. She stresses the importance of maintaining a strong commercial presence locally to address…

Thailand Kevin Peters, Managing Director of MSD in Thailand, highlights the strategic significance and strong performance of the affiliate as a top three pharmaceutical player in Thailand. Kevin goes on to share his mission to position MSD as an innovative partner of Thailand’s healthcare stakeholders in improving the outcomes, access, and…

Sweden Jakob Tellgren recently returned from MSD’s US headquarters to his home country of Sweden to take the helm of the Nordic and Baltic countries. He shares the importance of Sweden and the Nordics for the group and his plans to continue driving the outstanding performance of the affiliate while bringing…

Sweden The Top 20 pharma companies in Sweden ranked by sales in 2018. Out in front is Swiss giant Novartis with approx USD 256 million in sales, followed by MSD with USD 220 million and Pfizer with USD 212 million. The companies with the highest levels of sales growth since 2017…

Turkey Renan Ozyerli of MSD Turkey provides insights into the transformation of Turkey’s healthcare ecosystem over the past decade, highlighting how MSD works hand-in-hand with the government to broaden access to life-changing innovation. He also pinpoints MSD’s exceptional and enduring commitment to Turkey, which has led the company to emerge as…

Spain With Spain now on the road to economic recovery following the ravages of the global financial crisis, multinational pharmaceutical companies are seeing the country as a top investment destination once more thanks to a much-improved market access scenario, high-quality but affordable manufacturing capabilities and an enviable human resource base. As…

Spain Angel Fernandez, president and managing director of MSD Spain and Portugal, covers the company´s current pipeline and portfolio strategy. He also explains how the company collaborate with a wide variety of stakeholders.   What is the history of MSD in the Spanish market? Overall, MSD is a company with 127…

Cyprus   Jacqueline Anastassiades has been involved in the development of the Cypriot healthcare sector for more than 10 years as the Managing Director of MSD. With the upcoming healthcare reforms, she brings her expert insights into the key requirements the Cyprus national health system should validate as well as the…

UK Having just announced a major investment into a new UK Discovery Centre in London that is set to open in 2020, MSD is committed to leverage on the UK’s potential in driving forward early stage discovery. Louise Houson, Managing Director for the UK and Ireland explains the reasons for that…

Portugal The top 20 pharma companies in Portugal ranked by sales and market share for the year leading up to March 2018. MSD leads the way with EUR 148 million in sales and a 5.4 percent market share, followed by Mylan and Bayer.

India A strong supporter of public-private partnerships, MSD’s managing director in India, Vivek Kamath, explains how the company’s collaborative approach is the key to enhancing their reputation, improving patient outcomes and tackling unmet medical needs in India.   Mr. Kamath, you have worked for MSD for over four years and you…